HOOKIPA Pharma Inc.

Informe Stock NasdaqCM:HOOK

Capitalización de mercado: US$79.7m

Salud financiera de hoja de balance de HOOKIPA Pharma

Salud financiera controles de criterios 6/6

HOOKIPA Pharma tiene unos fondos propios totales de $95.1M y una deuda total de $1.0M, lo que sitúa su ratio deuda/fondos propios en 1.1%. Sus activos y pasivos totales son $164.0M y $69.0M respectivamente.

Información clave

1.2%

Ratio deuda-patrimonio

US$1.12m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$117.10m
PatrimonioUS$89.86m
Total pasivoUS$71.48m
Activos totalesUS$161.34m

Actualizaciones recientes sobre salud financiera

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Oct 01
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Apr 19
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Recent updates

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18
Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

Hookipa: Speculative Biotech With Key Catalysts In 2022

Mar 29

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Oct 01
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Checking Back In On HOOKIPA Pharma

Jun 22

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers

Jun 08

Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

Apr 19
Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?

If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

Mar 15
If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns

What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?

Jan 22
What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?

Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside

Dec 31

Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year

Dec 11
Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year

HOOKIPA Pharma prices public offering of common stock and preferred stock

Dec 09

Análisis de la situación financiera

Pasivos a corto plazo: HOOKLos activos a corto plazo ($139.5M) de la empresa superan a sus pasivos a corto plazo ($40.6M).

Pasivo a largo plazo: HOOKLos activos a corto plazo ($139.5M) superan a sus pasivos a largo plazo ($28.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: HOOK tiene más efectivo que su deuda total.

Reducción de la deuda: HOOK ha pasado de 8.7% a 1.1% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: HOOK tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: HOOK dispone de suficiente liquidez para 2.1 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 9.4% cada año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target